Outputs (584)

Misappropriation of the 1986 WHO analgesic ladder: the pitfalls of labelling opioids as weak or strong (2022)
Journal Article
Crush, J., Levy, N., Knaggs, R. D., & Lobo, D. N. (2022). Misappropriation of the 1986 WHO analgesic ladder: the pitfalls of labelling opioids as weak or strong. British Journal of Anaesthesia, 129(2), 137-142. https://doi.org/10.1016/j.bja.2022.03.004

Opioids have a vital role in alleviating pain from cancer and surgery. Despite good intentions, it is now recognised that the original WHO Cancer Pain Relief guidance from 1986, in which opioids were classified as either weak or strong, has been both... Read More about Misappropriation of the 1986 WHO analgesic ladder: the pitfalls of labelling opioids as weak or strong.

Some additional considerations on: “Finding the sweet spot: glycosylation mediated regulation of intestinal inflammation” (2022)
Journal Article
Monaghan, T. M., Kao, D., & Lauc, G. (2022). Some additional considerations on: “Finding the sweet spot: glycosylation mediated regulation of intestinal inflammation”. Mucosal Immunology, 15(3), Article 525. https://doi.org/10.1038/s41385-022-00512-z

Study to investigate the prevalence of human papillomavirus in Barrett's oesophagus using a novel screening methodology (2022)
Journal Article
White, J. R., Ragunath, K., Whitton, A., Marsh, E., Kaye, P., & Knight, G. (2022). Study to investigate the prevalence of human papillomavirus in Barrett's oesophagus using a novel screening methodology. BMJ Open Gastroenterology, 9(1), Article e000840. https://doi.org/10.1136/bmjgast-2021-000840

Introduction Human papillomavirus (HPV) is strongly associated with Barrett's dysplasia and oesophageal cancer suggesting a role in carcinogenesis. HPV persistence predicts treatment failure after endotherapy for Barrett's dysplasia. This pilot study... Read More about Study to investigate the prevalence of human papillomavirus in Barrett's oesophagus using a novel screening methodology.

Pilot Double-Blind Randomised Controlled Trial: Effects of Jejunal Nutrition on Postprandial Distress in Diabetic Gastropathy (J4G Trial) (2022)
Journal Article
Carneiro, L., White, J., Parker, H., Hoad, C., Tucker, E., Marciani, L., …Fox, M. (2022). Pilot Double-Blind Randomised Controlled Trial: Effects of Jejunal Nutrition on Postprandial Distress in Diabetic Gastropathy (J4G Trial). Nutrients, 14(7), Article 1321. https://doi.org/10.3390/nu14071321

Nausea, vomiting and abdominal pain in diabetic patients are often attributed to diabetic gastropathy (DG). Post-pyloric (“jejunal”) enteral nutrition (JN) may improve nutrition and glycaemia in difficult cases. The acute effects of JN on postprandia... Read More about Pilot Double-Blind Randomised Controlled Trial: Effects of Jejunal Nutrition on Postprandial Distress in Diabetic Gastropathy (J4G Trial).

A revised electronic version of RUCAM for the diagnosis of DILI (2022)
Journal Article
Hayashi, P. H., Lucena, M. I., Fontana, R. J., Bjornsson, E. S., Aithal, G. P., Barnhart, H., …Hoofnagle, J. H. (2022). A revised electronic version of RUCAM for the diagnosis of DILI. Hepatology, 76(1), 18-31. https://doi.org/10.1002/hep.32327

Background and Aims: Roussel Uclaf Causality Assessment Method (RUCAM) for DILI has been hindered by subjectivity and poor reliability. We sought to improve the RUCAM using data from the Drug-Induced Liver Injury Network (DILIN) and the Spanish DILI... Read More about A revised electronic version of RUCAM for the diagnosis of DILI.

Early Postoperative Supplementary Parenteral Nutrition (2022)
Journal Article
Ljungqvist, O., Gustafsson, U. O., & Lobo, D. N. (2022). Early Postoperative Supplementary Parenteral Nutrition. JAMA Surgery, 209, Article 118333. https://doi.org/10.1001/jamasurg.2022.0266

Molten salts have been used in solar thermal energy storage due to their high energy storage density, low cost and excellent chemical stability. However, their application is limited by “bad days” such as cloudy days and winter because the weak conce... Read More about Early Postoperative Supplementary Parenteral Nutrition.

HLA-DR polymorphism in SARS-CoV-2 infection and susceptibility to symptomatic COVID-19 (2022)
Journal Article
Astbury, S., Reynolds, C. J., Butler, D. K., Munoz-Sandoval, D. C., Lin, K., Pieper, F. P., …Altmann, D. M. (2022). HLA-DR polymorphism in SARS-CoV-2 infection and susceptibility to symptomatic COVID-19. Immunology, 166(1), 68-77. https://doi.org/10.1111/imm.13450

SARS-CoV-2 infection results in different outcomes ranging from asymptomatic infection to mild or severe disease and death. Reasons for this diversity of outcome include differences in challenge dose, age, gender, comorbidity and host genomic variati... Read More about HLA-DR polymorphism in SARS-CoV-2 infection and susceptibility to symptomatic COVID-19.

Treatment and Outcome of Autoimmune Hepatitis (AIH): Audit of 28 UK centres (2022)
Journal Article
Gordon, V., Adhikary, R., Appleby, V., Das, D., Day, J., Delahooke, T., …Gleeson, D. (2022). Treatment and Outcome of Autoimmune Hepatitis (AIH): Audit of 28 UK centres. Liver International, 42(7), 1571-1584. https://doi.org/10.1111/liv.15241

Background
With few data regarding treatment and outcome of patients with AIH outside of large centres we present such a study of patients with AIH in 28 UK hospitals of varying size and facilities.

Methods
Patients with AIH were identified in 1... Read More about Treatment and Outcome of Autoimmune Hepatitis (AIH): Audit of 28 UK centres.

System-level policies on appropriate opioid use, a multi-stakeholder consensus (2022)
Journal Article
Forget, P., Patullo, C., Hill, D., Ambekar, A., Baldacchino, A., Cata, J., …Gilbert, S. (2022). System-level policies on appropriate opioid use, a multi-stakeholder consensus. BMC Health Services Research, 22(1), Article 329. https://doi.org/10.1186/s12913-022-07696-x

Background: This consensus statement was developed because there are concerns about the appropriate use of opioids for acute pain management, with opposing views in the literature. Consensus statement on policies for system-level interventions may he... Read More about System-level policies on appropriate opioid use, a multi-stakeholder consensus.

Validation of the aMAP score to predict hepatocellular carcinoma development in a cohort of alcohol‐related cirrhosis patients (2022)
Journal Article
Liu, K., Yip, T. C. F., Masson, S., Fateen, W., Schwantes‐An, T., McCaughan, G. W., …Seth, D. (2022). Validation of the aMAP score to predict hepatocellular carcinoma development in a cohort of alcohol‐related cirrhosis patients. Liver Cancer International, 3(2), 99-104. https://doi.org/10.1002/lci2.47

Background and Aims
The aMAP score was recently devised to predict hepatocellular carcinoma (HCC) development. However, its performance was not tested in alcohol-related cirrhosis (ALC). We aimed to validate the aMAP score in a cohort of ALC patient... Read More about Validation of the aMAP score to predict hepatocellular carcinoma development in a cohort of alcohol‐related cirrhosis patients.